McKesson Corporation (MCK) Up 15.9% — Is This Strength Worth Buying Into?
McKesson Corporation (MCK) staged a powerful advance in the latest session, with shares jumping 15.93% to close at $952.94. That move represents a sharp single-day gain of $130.94 from the prior close at $822.00, signaling strong performance and decisive bullish activity. Trading was active, with volume reaching 771,818 shares, running ahead of the 90-day average of 693,766 and reinforcing the sense of conviction behind the latest upswing. The stock also extended its longer-term uptrend, advancing well beyond recent levels and firmly reasserting its leadership stance within the healthcare distribution space.
From a technical standpoint, McKesson is now trading well above its 52-week peak of $895.58 set on Nov. 26, 2025, putting the stock in fresh high ground and underscoring powerful upward momentum. At the latest close, shares stand more than $57 above that prior high and have surged far from the 52-week low of $570.51, highlighting a substantial recovery and ongoing strength over the past year. In comparison, many large-cap healthcare peers such as Medtronic (MDT), HCA Healthcare (HCA), and Cardinal Health (CAH) have seen more moderate recent moves, making MCK’s latest action stand out as particularly robust. Overall, the combination of a double-digit percentage advance, gains of over $100 per share in a single session, and heavier-than-normal trading activity points to a stock that is gaining ground aggressively and reinforcing its positive price trajectory.
Why McKesson Corporation Price is Moving Higher
McKesson’s latest move higher is being driven squarely by fundamentals. The company delivered a standout fiscal 2026 Q3 report on Feb. 4, with revenue climbing 11.4% year over year to $106.2 billion and adjusted EPS jumping 38% to $9.59, comfortably ahead of expectations. Management reinforced this strength by raising full-year adjusted EPS guidance to a range of $38.80–$39.20, signaling confidence in the sustainability of current momentum. On top of the year-over-year acceleration, McKesson also posted solid sequential performance, with latest-quarter revenue up 5.4% from the prior period, underscoring steady operational growth in its core health care distribution and services businesses.
Investors are also reacting to a series of favorable strategic and market developments that support the bullish sentiment. The recent completion of the sale of McKesson’s Norwegian retail and distribution operations to NorgesGruppen advances its broader strategy to streamline the portfolio and sharpen its focus on higher-return markets. Analyst commentary has reinforced this constructive backdrop: Wells Fargo and Mizuho both raised their price targets following the earnings beat, while TD Cowen reiterated its positive stance, contributing to a consensus “Moderate Buy” view. Against this backdrop of double‑digit revenue growth, expanding earnings, and portfolio simplification, market participants appear more willing to reward McKesson with a higher valuation multiple, helping propel the stock to new highs and fueling the current upside momentum.
What is the McKesson Corporation Rating - Should I Buy?
Weiss Ratings assigns MCK an A rating. Current recommendation is Buy. The stock was upgraded on 11/18/2025, signaling that its overall risk/reward profile has moved into our highest category. An A rating places McKesson Corporation among the strongest names we follow, indicating that, based on our models, it has delivered attractive performance while maintaining a relatively controlled risk profile.
A key strength behind this top-tier assessment is the Excellent Growth Index, supported by double‑digit revenue growth of 10.14%. McKesson is also backed by an Excellent Efficiency Index, meaning the company has been using capital and assets effectively to generate returns, an important factor given its modest 1.04% profit margin in a low‑margin distribution business. The Good Total Return Index further supports the A rating, indicating that shareholders have historically been rewarded for the risks taken.
On the risk side, McKesson benefits from a Good Volatility Index and a Good Solvency Index. Together, these point to a balance sheet and trading profile that, while not perfect, have been strong enough to support an A rating when combined with its growth and efficiency strengths. The primary weak spot is the Weak Dividend Index, which tells income-focused investors that the stock is less compelling purely as a yield play, even though the overall investment profile is strong.
Within health care, McKesson’s A rating stands above Medtronic plc (MDT, B), HCA Healthcare, Inc. (HCA, B), and Cardinal Health, Inc. (CAH, B). That relative strength positions MCK as a higher‑quality, more reliable choice in its sector for investors prioritizing long‑term, risk‑adjusted performance.
About McKesson Corporation
McKesson Corporation is one of the largest and most established healthcare services and distribution companies in the world, with roots dating back to 1833. Headquartered in Irving, Texas, the company plays a central role in the health care equipment and services ecosystem by ensuring that medicines, medical supplies, and critical information flow efficiently from manufacturers to the points of care. Through its U.S. Pharmaceutical segment, McKesson distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceuticals, along with other healthcare-related products. It also supports community-based oncology and other specialty practices with practice management, clinical support, and business solutions, as well as operational and clinical technology for pharmacies.
Beyond distribution, McKesson has built a strong position in healthcare technology and patient access solutions. Its Prescription Technology Solutions (RxTS) segment connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to address medication access and affordability. This platform provides prescription decision support, price transparency, benefit insight, dispensing support, electronic prior authorization, and third-party logistics services, helping reduce friction across the medication journey. The Medical-Surgical Solutions segment further broadens McKesson’s reach by supplying medical-surgical products, logistics, and biomedical maintenance to physician offices, surgery centers, nursing homes, post-acute care facilities, hospital reference labs, and home health agencies.
Internationally, McKesson delivers medicines, supplies, and information technology solutions to retail pharmacies, hospitals, long-term care centers, clinics, and other institutions, while also providing logistics and distribution services for manufacturers. This integrated network—spanning pharmaceuticals, medical-surgical supplies, and advanced technology solutions—supports McKesson’s role as a key infrastructure provider in global healthcare, with scale, reliability, and deep industry relationships serving as core competitive advantages.
Investor Outlook
With an A (Buy) Weiss Rating, McKesson Corporation (MCK) appears favorably positioned for potential continued gains as investors watch how the Health Care landscape and reimbursement trends evolve. The key will be whether MCK can sustain its recent momentum while maintaining operational strength that supports its current Buy assessment. See full rankings of all A-rated Health Care stocks inside the Weiss Stock Screener.
--